Wednesday, 3 April 2019
Tuesday, 2 April 2019
Taconic obtains licence to NIDDK's Wild Mouse gut microbiome
KUALA LUMPUR, April 2 (Bernama) -- Taconic Biosciences has obtained a licence to the Wild Mouse gut microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NIDDK is part of the National Institutes of Health, according to a statement.
Taconic licensed the Wild Mouse gut microbiota from NIDDK as a complement to its existing microbiome solution portfolio, which includes germ-free mice and custom microbiota associations.
“The Wild Mouse gut microbiota model will allow researchers to identify new host-microbe relationships and potential for determining new disease protection mechanisms,” said Taconic (microbiome products and services) associate director, Dr Alexander Maue.
The Wild Mouse gut microbiota can be banked for future use and/or maintained in a laboratory mouse breeding colony for immediate research purposes.
In drug discovery research, the microbiome is used to clarify the impact of varying microbiomes on the efficacy of potential therapeutics and also to potentially identify new drug targets.
By having a defined microbiome standard via the NIDDK Wild Mouse gut microbiome, customers now have a basis for comparison to better understand the microbiome of their research models.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. It provides animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.
-- BERNAMA
NIDDK is part of the National Institutes of Health, according to a statement.
Taconic licensed the Wild Mouse gut microbiota from NIDDK as a complement to its existing microbiome solution portfolio, which includes germ-free mice and custom microbiota associations.
“The Wild Mouse gut microbiota model will allow researchers to identify new host-microbe relationships and potential for determining new disease protection mechanisms,” said Taconic (microbiome products and services) associate director, Dr Alexander Maue.
The Wild Mouse gut microbiota can be banked for future use and/or maintained in a laboratory mouse breeding colony for immediate research purposes.
In drug discovery research, the microbiome is used to clarify the impact of varying microbiomes on the efficacy of potential therapeutics and also to potentially identify new drug targets.
By having a defined microbiome standard via the NIDDK Wild Mouse gut microbiome, customers now have a basis for comparison to better understand the microbiome of their research models.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. It provides animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.
-- BERNAMA
New blood: Terumo BCT CEO set to shape future of blood, cell technologies
KUALA LUMPUR, April 2 (Bernama) -- New Terumo BCT president and chief executive officer, Antoinette Gawin has expanded the company beyond its heritage in working with blood centres and hospitals to serve rapidly growing areas of healthcare.
She focuses on the company’s potential to treat disease and play a greater role in cell therapy and regenerative medicine, to serve more patients as Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas.
“Our innovations automate complex processes, help researchers and clinicians unlock the healing potential of an individual’s genetic material. We must diversify our portfolio to fund continued innovation in this cost-conscious healthcare environment and remain relevant to our customers,” said Gawin.
Strategies include embedding products in the cell therapy manufacturing process, increasing the awareness of therapeutic apheresis as a treatment to address autoimmune diseases and building infrastructure in growth geographies, among others.
Gawin, who succeeds David Perez, will oversee the company with nearly US$1 billion (US$1 = RM4.08) in revenue and 7,000 associates supporting customers in 130 countries.
She joined Terumo BCT in 2016 as executive vice-president (global commercial), bringing nearly 30 years’ experience directing diverse global teams and transformational change across Baxter and GE.
Terumo BCT is a biomedical company and global leader in blood component, therapeutic apheresis and cell therapy technologies. For more information, contact https://www.terumobct.com.
-- BERNAMA
She focuses on the company’s potential to treat disease and play a greater role in cell therapy and regenerative medicine, to serve more patients as Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas.
“Our innovations automate complex processes, help researchers and clinicians unlock the healing potential of an individual’s genetic material. We must diversify our portfolio to fund continued innovation in this cost-conscious healthcare environment and remain relevant to our customers,” said Gawin.
Strategies include embedding products in the cell therapy manufacturing process, increasing the awareness of therapeutic apheresis as a treatment to address autoimmune diseases and building infrastructure in growth geographies, among others.
Gawin, who succeeds David Perez, will oversee the company with nearly US$1 billion (US$1 = RM4.08) in revenue and 7,000 associates supporting customers in 130 countries.
She joined Terumo BCT in 2016 as executive vice-president (global commercial), bringing nearly 30 years’ experience directing diverse global teams and transformational change across Baxter and GE.
Terumo BCT is a biomedical company and global leader in blood component, therapeutic apheresis and cell therapy technologies. For more information, contact https://www.terumobct.com.
-- BERNAMA
Subscribe to:
Posts (Atom)